This article is more than 5 years old. Information may no longer be current.

VIDEO: Genetic screening rapidly links elderly AML patients to targeted therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — Brittany K. Ragon, MD, a leukemia transplant specialist in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Carolinas HealthCare System, reviews findings at the ASH Annual Meeting and Exposition from the BEAT-AML study, which showed that clinicians were able to use genetic information to match elderly patients with acute myeloid leukemia to molecularly targeted therapies within 1 week of diagnosis.

The trial is the first precision medicine trial focused on elderly patients aged older than 60 years with AML, according to Ragon.

“About 96% of patients were ... screened and put on a particular treatment arm within 7 days,” she says. “ I think that is a huge accomplishment in our field.”

Reference:

Burd A, et al. Abstract 559. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Disclosure: Ragon reports no relevant financial disclosures.